| Company Name | Takeda Taiwan |
|---|---|
| Protocol Number | Vedolizumab-5026 |
| Title of Study | Safety and Effectiveness of Vedolizumab IV in Real World Clinical Practice in Taiwan: A Registry-Based Study |
| Primary Objective | To assess the safety of vedolizumab IV in patients with UC and CD in Taiwan. To assess the effectiveness of vedolizumab IV in patients with UC and CD in Taiwan. |
| Number of Sites | At least 14 (all of the sites participating in “Prospective IBD patients Registration in Taiwan/台灣發炎性腸道疾病資料前瞻性登錄計畫”) |
| Period of Study | From：August 2017 to：May 2020 |
| Number of Patients | At least 350人 |
| IRB Approval Date | 臺大醫院: Sep/19/2016 |
| Publication Plan / Date | May 2021 |
